1. Home
  2. QUAD vs PBYI Comparison

QUAD vs PBYI Comparison

Compare QUAD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quad Graphics Inc

QUAD

Quad Graphics Inc

HOLD

Current Price

$8.25

Market Cap

396.6M

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$7.87

Market Cap

364.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUAD
PBYI
Founded
1971
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Publishing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.6M
364.9M
IPO Year
2010
2011

Fundamental Metrics

Financial Performance
Metric
QUAD
PBYI
Price
$8.25
$7.87
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$9.93
N/A
AVG Volume (30 Days)
146.4K
229.9K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
5.71%
N/A
EPS Growth
150.47
N/A
EPS
0.13
N/A
Revenue
$2,419,900,000.00
$27,685,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$61.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.01
$3.03
52 Week High
$8.64
$8.41

Technical Indicators

Market Signals
Indicator
QUAD
PBYI
Relative Strength Index (RSI) 71.21 64.43
Support Level $7.33 $6.41
Resistance Level $8.64 N/A
Average True Range (ATR) 0.23 0.36
MACD 0.08 0.09
Stochastic Oscillator 98.06 75.78

Price Performance

Historical Comparison
QUAD
PBYI

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: